NCT07515456 Theophylline, Versus Sumatriptan and Gabapentin in The Treatment of Post-Dural Puncture Headache
| NCT ID | NCT07515456 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tanta University |
| Condition | Theophylline |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2024-12-01 |
| Primary Completion | 2026-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 75 participants in total. It began in 2024-12-01 with a primary completion date of 2026-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to compare the safety and efficacy of theophylline, sumatriptan, and gabapentin in the treatment of post-dural puncture headache.
Eligibility Criteria
Inclusion Criteria: * Age from 21 to 50 years. * Both sexes. * American Society of Anesthesiologists (ASA) physical status ≤ II. * Patient's selection for this study will be based on clinical diagnosis suggesting post-dural puncture headache (PDPH) based on the International Headache Society criteria. * Patients with numeric rating scale (NRS) of ≥ 5. Exclusion Criteria: * Pregnant women. * History of; chronic headache, cluster headache, migraine, convulsions, cerebrovascular accident, and previous neurological diseases. * Signs of meningismus. * Dysrhythmia. * Hypertension. * Ischemic heart disease. * Hyperthyroidism. * Peripheral vascular disease (ischemic colitis). * Liver or renal impairment. * Use of selective serotonin reuptake inhibitors. * Use of ergotamine derivatives in the past 24 hours. * Use of monoamine oxidase inhibitors in the last 2 weeks. * Use of any kind of opiates. * Allergy to the study medications and any contraindication of oral intake.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07515456 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 50 Years, studying Theophylline. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07515456 currently recruiting?
Yes, NCT07515456 is actively recruiting participants. Contact the research team at asmaaragabeid@gmail.com for enrollment information.
Where is the NCT07515456 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT07515456 clinical trial?
NCT07515456 is sponsored by Tanta University. The trial plans to enroll 75 participants.